Pharma News

The widespread misuse of skin creams and lotions that contain steroids in India is harmful and out of control, warns a Gujarat-based dermatologist.

Scientists have discovered a new compound that shows promise for treating deadly skin cancers like melanoma that are resistant or unresponsive to leading therapies today.

Japanese scientists have discovered a protein, found in humans, that has inhibitory effects on the human immuno-deficiency virus (HIV), the media reported on Wednesday.

The bacteria in your gut may help control when and how much you eat as researchers have found that 20 minutes after a meal they produce proteins that influence activation of appetite-regulating neurons in the brain.

The European Commission (EC) has approved Novartis' Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumour necrosis factor (anti-TNF) therapy.

Pfizer and IIT-Delhi on Tuesday said they have launched an incubation accelerator initiative at the later's campus for Indian startup companies as well as individuals.

[adsense:336x280:8701650588]

The U.S. Food and Drug Administration  approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

Amgen announced the European Commission (EC) granted marketing authorization for Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Kyprolis is the first irreversible proteasome inhibitor approved in the European Union (EU) for use in combination treatment of patients with relapsed multiple myeloma

AstraZeneca, a global, innovation-driven biopharmaceutical business, announced three new partnerships that will deliver industry-leading technologies to drive the AstraZeneca MRC UK Centre for Lead Discovery in the search for novel small molecule medicines. The partnerships will ensure state-of-the-art screening and compound management at the facility, which will be located within the company’s new global R&D centre at the Cambridge Biomedical Campus. It will screen around 2 million chemical structures per target to find new compounds for disease targets.

Following the Rs.640-crore class action suit filed by the government against Nestle India, the apex consumer court on Tuesday said "unending testing of Maggi samples cannot go on".